Regarding siRNA delivery, Zhao et al.45,75 prepared an inhalable and mucus-penetrative NP system incorporating siRNA against IL11 and KRAS-mutant NSCLC based on ionizable lipid compound G0-C14. Here, KRAS is linked to non-small cell lung carcinoma.